# GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification

> **NCT03618667** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 13 (actual)

## Conditions studied

- Glioblastoma, Adult
- EGFR Amplification

## Interventions

- **DRUG:** GC1118

## Key facts

- **NCT ID:** NCT03618667
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-22
- **Primary completion:** 2018-09-08
- **Final completion:** 2022-04-28
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2023-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03618667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03618667, "GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03618667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*